Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01126879 · ClinicalTrials.gov registry record · Phase 2
Genistein in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01126879 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 12 participants.
The verdict
NCT01126879, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer.
Interventions
- OTHER placebo
- PROCEDURE therapeutic conventional surgery
- DIETARY_SUPPLEMENT genistein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-02-03 |
| Est. Completion | 2013-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01126879
The ClinicalTrials.gov registry entry for NCT01126879 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01126879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01126879 about?
NCT01126879 is a clinical study titled "Genistein in Treating Patients With Prostate Cancer". RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer.
What is the current status of trial NCT01126879?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2011-02-03. Estimated completion is 2013-12-28.
What interventions are being tested in trial NCT01126879?
The interventions under investigation include: placebo (OTHER), therapeutic conventional surgery (PROCEDURE), genistein (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01126879?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.